Juluca and Glaucoma - a phase IV clinical study of FDA data

Summary:

Glaucoma is reported as a side effect among people who take Juluca (dolutegravir sodium; rilpivirine hydrochloride), especially for people who are male, 50-59 old, have been taking the drug for 2 - 5 years also take Diovan, and have High blood pressure.

The phase IV clinical study analyzes which people have Glaucoma when taking Juluca. It is created by eHealthMe based on reports of 1,728 people who have side effects when taking Juluca from the FDA, and is updated regularly.

What is Juluca?

Juluca has active ingredients of dolutegravir sodium; rilpivirine hydrochloride. eHealthMe is studying from 1,732 Juluca users. Check the latest studies of Juluca.

What is Glaucoma?

Glaucoma (increased fluid pressure in the eye with vision loss) is found to be associated with 1,233 drugs and 1,657 conditions by eHealthMe. Check the latest studies of Glaucoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

1,728 people reported to have side effects when taking Juluca.
Among them, 14 people (0.81%) have Glaucoma.

Among these 14 people:

How long have people been on Juluca when they have Glaucoma? *

What is the gender of people who have Glaucoma when taking Juluca? *

female: 0.0 %
male: 100 %

What is the age of people who have Glaucoma when taking Juluca? *

What are other drugs people take besides Juluca? *

What are other side effects people have besides Glaucoma? *

Type 2 Diabetes: 14 people, 100.00%
Hepatic Steatosis (fatty liver disease): 14 people, 100.00%
Diabetes: 9 people, 64.29%
Oesophageal Carcinoma (cancer tumour of oesophagus): 4 people, 28.57%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 14 people, 100.00%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 14 people, 100.00%
Hyperlipidaemia (presence of excess lipids in the blood): 14 people, 100.00%
Hiv Infection: 14 people, 100.00%
High Blood Pressure: 14 people, 100.00%
Diabetes: 6 people, 42.86%

* Approximation only. Some reports may have incomplete information.

Do you take Juluca and have Glaucoma?

- Check whether Glaucoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Juluca:

Juluca (1,732 reports)

Glaucoma treatments and more:

Glaucoma (61,928 reports)

How severe was Glaucoma and when was it recovered:

Glaucoma in Juluca

Expand to all the drugs that have ingredients of dolutegravir sodium; rilpivirine hydrochloride:

Glaucoma and drugs with ingredients of dolutegravir sodium; rilpivirine hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Juluca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glaucoma:

Glaucoma (1,233 drugs)

Browse all the conditions that are associated with Glaucoma:

Glaucoma (1,657 conditions)

Related publications that referenced our studies

Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .
Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on dolutegravir sodium; rilpivirine hydrochloride (the active ingredients of Juluca) and Juluca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.